This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiong, Y.-Q.
Right arrow Articles by Bayer, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiong, Y.-Q.
Right arrow Articles by Bayer, A. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1999, p. 1737-1742, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Comparative Efficacies of Liposomal Amikacin (MiKasome) plus Oxacillin versus Conventional Amikacin plus Oxacillin in Experimental Endocarditis Induced by Staphylococcus aureus: Microbiological and Echocardiographic Analyses

Yan-Qiong Xiong,1,* Leon Iri Kupferwasser,1 Philip M. Zack,2 and Arnold S. Bayer1,3

St. John's Cardiovascular Research Center, LAC-UCLA Medical Center, Torrance, California 905091; NeXstar Pharmaceuticals, Inc., Boulder, Colorado 803012; and UCLA School of Medicine, Los Angeles, California 900243

Received 28 December 1998/Returned for modification 1 April 1999/Accepted 23 April 1999

Optimal treatment strategies for serious infections caused by Staphylococcus aureus have not been fully characterized. The combination of a beta -lactam plus an aminoglycoside can act synergistically against S. aureus in vitro and in vivo. MiKasome, a new liposome-encapsulated formulation of conventional amikacin, significantly prolongs serum half-life (t1/2) and increases the area under the concentration-time curve (AUC) compared to free amikacin. Microbiologic efficacy and left ventricular function, as assessed by echocardiography, were compared in animals administered either oxacillin alone or oxacillin in combination with conventional amikacin or MiKasome in a rabbit model of experimental endocarditis due to S. aureus. In vitro, oxacillin, combined with either free amikacin or MiKasome, prevented the bacterial regrowth observed with aminoglycosides alone at 24 h of incubation. Rabbits with S. aureus endocarditis were treated with either oxacillin alone (50 mg/kg, given intramuscularly three times daily), oxacillin plus daily amikacin (27 mg/kg, given intravenously twice daily), or oxacillin plus intermittent MiKasome (160 mg/kg, given intravenously, a single dose on days 1 and 4). The oxacillin-alone dosage represents a subtherapeutic regimen against the infecting strain in the endocarditis model (L. Hirano and A. S. Bayer, Antimicrob. Agents Chemother. 35:685-690, 1991), thus allowing recognition of any enhanced bactericidal effects between oxacillin and either aminoglycoside formulation. Treatment was administered for either 3 or 6 days, and animals were sacrificed after each of these time points or at 5 days after a 6-day treatment course (to evaluate for posttherapy relapse). Left ventricular function was analyzed by utilizing serial transthoracic echocardiography during treatment and posttherapy by measurement of left ventricular fractional shortening. At all sacrifice times, both combination regimens significantly reduced S. aureus vegetation counts versus control counts (P < 0.05). In contrast, oxacillin alone did not significantly reduce S. aureus vegetation counts after 3 days of therapy. Furthermore, at this time point, the two combinations were significantly more effective than oxacillin alone (P < 0.05). All three regimens were effective in significantly decreasing bacterial counts in the myocardium during and after therapy compared to controls (P < 0.05). In kidney and spleen abscesses, all regimens significantly reduced bacterial counts during therapy (P < 0.0001); however, only the combination regimens prevented bacteriologic relapse in these organs posttherapy. By echocardiographic analysis, both combination regimens yielded a significant physiological benefit by maintaining normal left ventricular function during treatment and posttherapy compared with oxacillin alone (P < 0.001). These results suggest that the use of intermittent MiKasome (similar to daily conventional amikacin) enhances the in vivo bactericidal effects of oxacillin in a severe S. aureus infection model and preserves selected physiological functions in target end organs.

* Corresponding author. Mailing address: Department of Medicine, Division of Infectious Diseases, St. John's Cardiovascular Research Center, Bldg. RB-2, LAC-Harbor UCLA Medical Center, 1000 West Carson St., Torrance, CA 90509. Phone: (310) 222-6423. Fax: (310) 782-2016. E-mail: xiong{at}humc.edu.

Antimicrobial Agents and Chemotherapy, July 1999, p. 1737-1742, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Zhu, Y., Xiong, Y. Q., Sadykov, M. R., Fey, P. D., Lei, M. G., Lee, C. Y., Bayer, A. S., Somerville, G. A. (2009). Tricarboxylic Acid Cycle-Dependent Attenuation of Staphylococcus aureus In Vivo Virulence by Selective Inhibition of Amino Acid Transport. Infect. Immun. 77: 4256-4264 [Abstract] [Full Text]  
  • Yang, S.-J., Xiong, Y. Q., Dunman, P. M., Schrenzel, J., Francois, P., Peschel, A., Bayer, A. S. (2009). Regulation of mprF in Daptomycin-Nonsusceptible Staphylococcus aureus Strains. Antimicrob. Agents Chemother. 53: 2636-2637 [Abstract] [Full Text]  
  • Skiadas, I., Pefanis, A., Papalois, A., Kyroudi, A., Triantafyllidi, H., Tsaganos, T., Giamarellou, H. (2007). Dexamethasone as Adjuvant Therapy to Moxifloxacin Attenuates Valve Destruction in Experimental Aortic Valve Endocarditis Due to Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2848-2854 [Abstract] [Full Text]  
  • Xiong, Y. Q., Willard, J., Kadurugamuwa, J. L., Yu, J., Francis, K. P., Bayer, A. S. (2005). Real-Time In Vivo Bioluminescent Imaging for Evaluating the Efficacy of Antibiotics in a Rat Staphylococcus aureus Endocarditis Model. Antimicrob. Agents Chemother. 49: 380-387 [Abstract] [Full Text]  
  • Kupferwasser, L. I., Yeaman, M. R., Shapiro, S. M., Nast, C. C., Bayer, A. S. (2002). In Vitro Susceptibility to Thrombin-Induced Platelet Microbicidal Protein Is Associated With Reduced Disease Progression and Complication Rates in Experimental Staphylococcus aureus Endocarditis: Microbiological, Histopathologic, and Echocardiographic Analyses. Circulation 105: 746-752 [Abstract] [Full Text]  
  • Siaperas, P., Pefanis, A., Iliopoulos, D., Katsarolis, I., Kyroudi-Voulgari, A., Donta, I., Karayiannakos, P., Giamarellou, H. (2001). Evidence of Less Severe Aortic Valve Destruction after Treatment of Experimental Staphylococcal Endocarditis with Vancomycin and Dexamethasone. Antimicrob. Agents Chemother. 45: 3531-3537 [Abstract] [Full Text]  
  • Schiffelers, R., Storm, G., Bakker-Woudenberg, I. (2001). Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 48: 333-344 [Abstract] [Full Text]  
  • Schiffelers, R. M., Storm, G., ten Kate, M. T., Bakker-Woudenberg, I. A. J. M. (2001). Therapeutic Efficacy of Liposome-Encapsulated Gentamicin in Rat Klebsiella pneumoniae Pneumonia in Relation to Impaired Host Defense and Low Bacterial Susceptibility to Gentamicin. Antimicrob. Agents Chemother. 45: 464-470 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»